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As neuroscientists, we were intrigued when Huang et al. (1)
reported that miR101 can attenuate pulmonary fibrosis (PF)2
through suppression of Wnt family member 5A (WNT5A).
Accumulating evidence suggests that prima facie unrelated dis-
orders in multiple fields of medicine share fundamental molec-
ular pathways. For example, PF associates with cognitive impair-
ment (2). It is reasonable to presume that such links would be due
to hypoxia and general inflammation, but could there be a
deeper connection? BothmiR101 and miR27b expression lev-
els were significantly reduced in more severe PF cases (1).
These same miRNA are implicated and reduced (3, 4) in Alz-
heimer’s disease (AD). Interestingly, while miR101 levels are
reduced in late-stage AD brain samples, an miRNA associated
with AD and Parkinson’s disease, miR153, is not (5). Notably,
miR27b regulates peroxisome proliferator–activated receptor
 (PPAR), and PPAR disruption is implicated in bothADand
PF (3).Wnt signaling disruption is a well-knownmolecular fea-
ture of AD (6). That two miRNA species are both down-regu-
lated and pathways they regulate are linked to specific pulmo-
nary and neurological disorders is noteworthy. If we want to
take a broader view of connection or divergence of progressive
disorders, we also can consider that miRNAs usually have mul-
tiple mRNA targets. In addition to regulating Wnt signaling,
miR101 regulates levels of theA-precursor protein (APP) and,
by extension, its neurotoxic processing product, A (4). APP, as
such, has not been directly implicated in PF, but it would not
be unreasonable to propose that disruption of miR101 would
impact several vital signaling and expression pathways. Disrup-
tion of a fundamental, multiorgan-wide pathway such as Wnt
or PPAR signaling could be a broad precursor to multiple dis-
orders, with specificity to be determined by other interactions.
This suggests the potential for developing a therapeutic strat-
egy to utilize common dysregulation of specific miRNAs for
disparate diseases.
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